Maryam Abdussamad, Grace Katz, Jie Cheng, Chinmayee Mehta, Fernando Andres-Martin, Danial Mahmood, Princy Kumar, Marta Catalfamo
{"title":"IL-27 effects on HIV<sub>Gag</sub>-specific CD4 and CD8 T cell function.","authors":"Maryam Abdussamad, Grace Katz, Jie Cheng, Chinmayee Mehta, Fernando Andres-Martin, Danial Mahmood, Princy Kumar, Marta Catalfamo","doi":"10.3389/fviro.2025.1600802","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In people with HIV (PWH) and suppressed viral replication by antiretroviral therapy persistent T cell activation and inflammation are important contributors of the increased risk of morbidity and mortality. CD8 T cells express checkpoint receptors and are dysfunctional. IL-27, a member of the IL-6/IL-12 family has shown anti-viral properties against various human viruses, including HIV. The role of IL-27 on HIV-specific T cells remains unclear. We hypothesized that IL-27 will enhance the function of HIV-specific T cells.</p><p><strong>Methods: </strong>IL-27 effects on T cell function was evaluated by measuring cytokine secretion, proliferation, and cytotoxicity.</p><p><strong>Results: </strong>Our findings show that IL-27 upregulates cytokine secretion and cytotoxic potential, and trafficking of proliferating HIV-specific CD8 T cells expressing checkpoint receptors TIGIT and PD-1. Unbiased clustering analysis showed that IL-27 may have differential effects on distinct populations of HIV-specific T cells.</p><p><strong>Conclusion: </strong>Altogether these results suggest that IL-27 may enhance T cell function in the setting of chronic HIV infection.</p>","PeriodicalId":73114,"journal":{"name":"Frontiers in virology","volume":"5 ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12700625/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in virology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fviro.2025.1600802","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: In people with HIV (PWH) and suppressed viral replication by antiretroviral therapy persistent T cell activation and inflammation are important contributors of the increased risk of morbidity and mortality. CD8 T cells express checkpoint receptors and are dysfunctional. IL-27, a member of the IL-6/IL-12 family has shown anti-viral properties against various human viruses, including HIV. The role of IL-27 on HIV-specific T cells remains unclear. We hypothesized that IL-27 will enhance the function of HIV-specific T cells.
Methods: IL-27 effects on T cell function was evaluated by measuring cytokine secretion, proliferation, and cytotoxicity.
Results: Our findings show that IL-27 upregulates cytokine secretion and cytotoxic potential, and trafficking of proliferating HIV-specific CD8 T cells expressing checkpoint receptors TIGIT and PD-1. Unbiased clustering analysis showed that IL-27 may have differential effects on distinct populations of HIV-specific T cells.
Conclusion: Altogether these results suggest that IL-27 may enhance T cell function in the setting of chronic HIV infection.